San Jose, CA – According to filings with the U.S. Securities and Exchange Commission, TriFlo Cardiovascular is raising $4,590,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Thierry Thaure played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TriFlo Cardiovascular

TriFlo is focused on taking to clinical trials a unique minimally invasive transcatheter solution to treat tricuspid valve regurgitation. TriFlo Cardiovascular is a biotechnology firm working in stealth mode.

To learn more about TriFlo Cardiovascular, visit http://triflocv.com/

Contact:
Thierry Thaure, President and Chief Executive Officer
626-793-7134

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved